DNMT3A and acute myeloid leukemia: Concurrent homozygous loss of Dnmt3a cooperates with KrasG12D to accelerate disease progression and leads to development of AML in approximately 30% of mice, though heterozygous loss of Dnmt3a had no effect (84).